XML 93 R74.htm IDEA: XBRL DOCUMENT v3.19.1
Income Taxes - Schedule of Income Tax Rate Reconciliation (Details)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]    
Computed tax benefit at federal statutory rate 21.00% 34.00%
Research and development and other credits 1.00% 2.00%
Re-rate of federal net deferred tax assets 0.00% (38.00%)
Permanent differences (3.00%) (8.00%)
Change in valuation allowance 4.00% (32.00%)
Establish deferred tax liability for AgeX/OncoCyte shares at deconsolidation 8.00% 17.00%
Deconsolidation of AgeX and subsidiaries net deferred tax assets (28.00%) 0.00%
State tax benefit, net of effect on federal income taxes 0.00% 27.00%
Foreign rate differential (2.00%) (2.00%)
Income tax benefit 1.00% 0.00%